Advertisement
UK markets open in 7 hours 26 minutes
  • NIKKEI 225

    39,103.22
    +486.12 (+1.26%)
     
  • HANG SENG

    18,868.71
    -326.89 (-1.70%)
     
  • CRUDE OIL

    76.90
    +0.03 (+0.04%)
     
  • GOLD FUTURES

    2,333.10
    -4.10 (-0.18%)
     
  • DOW

    39,065.26
    -605.78 (-1.53%)
     
  • Bitcoin GBP

    53,257.63
    -1,171.35 (-2.15%)
     
  • CMC Crypto 200

    1,463.93
    -38.73 (-2.58%)
     
  • NASDAQ Composite

    16,736.03
    -65.51 (-0.39%)
     
  • UK FTSE All Share

    4,543.84
    -16.71 (-0.37%)
     

Novavax to Participate in BofA Securities 2024 Health Care Conference

GAITHERSBURG, Md., May 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the BofA Securities 2024 Health Care Conference.

Conference Details:



Fireside Chat


Date:

Wednesday, May 15, 2024

Time:

3:00 – 3:30 p.m. Pacific Daylight Time (PDT)

Location:

Encore Hotel in Las Vegas, NV

Moderator:

Alec Stranahan, PhD, Equity Research – U.S. Biopharma

Novavax participant:

John C. Jacobs, President and Chief Executive Officer



Conference


Event:

Investor Meetings

Date:

Wednesday, May 15, 2024

Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

ADVERTISEMENT

Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
202-709-5563
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)
Novavax Logo (PRNewsfoto/Novavax)

 

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2024-health-care-conference-302143793.html

SOURCE Novavax, Inc.